In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Great. Thanks, everyone, for joining. My name is Scott Schoenhaus. I am the health care tech equity analyst here at KeyBanc. We're a pleasure to have Ben Taylor, CFO of Recursion for a fireside chat.

Brian Beers is a digital editor, writer, Emmy-nominated producer, and content expert with 15+ years of experience writing about corporate finance & accounting, fundamental analysis, and investing.

Nvidia's recent $700 million acquisition of Run:ai enhances GPU access and infrastructure flexibility. The acquisition of OctoAI for $250 million bolsters Nvidia's generative AI tools portfolio.

Silver pulls back from $32.55 resistance, with key support at $31.81. Traders await NFP data for the next market move. Gold consolidates near record highs as overbought RSI signals a potential ...